Latest news with #DanVahdat
Yahoo
3 days ago
- Health
- Yahoo
Huma launches genAI clinical documentation tool
British healthtech company Huma Therapeutics has initiated the global launch of Hi Scribe, a generative AI (genAI) clinical documentation tool designed to automate and streamline the creation of clinical notes. Powered by over 60 million consultations conducted by eConsult, which Huma acquired last year, Hi Scribe is available through the Huma Cloud Platform (HCP), providing real time clinical documentation automation and the generation of structured clinical notes that can be directly integrated into electronic health record (EHR) systems. Hi Scribe is already launched in the UK to 870 practices, covering around 10 million patients, with write-back and coding capabilities for the EHR systems EMIS and SystmOne. Now rolling out across more than 4,500 health systems and clinics powered by Huma technologies, worldwide, Huma CEO and founder Dan Vahdat stated that administrative burdens such as process compliance and accurate billing remain some of the 'greatest challenges' facing healthcare systems globally. 'Hi Scribe gives clinicians critical time back, allowing them to focus on what matters most: their patients,' said Vahdat. Initiation of the tool's global launch follows the UK's National Health Service (NHS) England guidance around using AI-enabled scribing products in healthcare settings that was issued in April. Relating to best practices surrounding controls and implementation, the NHS guidelines advise healthcare systems to integrate such AI products with their principal EHR system and to ensure legal and regulatory requirements are factored into the procurement and implementation of their chosen products. Dr Murray Ellender, head of UK Healthcare at Huma commented: 'By leveraging genAI with strong regulatory governance, we are ensuring safe, effective, and efficient care. We are excited in the near future to start helping care providers with intelligent suggestions for next steps — ensuring that nothing is left unnoticed.' Huma recently announced a partnership with growth equity company Eckuity to support its development of technology infrastructure to support ongoing plans to acquire companies and launch digital solutions across the healthcare space. "Huma launches genAI clinical documentation tool" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
3 days ago
- Business
- Business Upturn
Huma Deploys Hi Scribe to Automate Clinical Documentation and Billing Using AI
New York, June 05, 2025 (GLOBE NEWSWIRE) — Huma Therapeutics, the global healthcare AI company, today announced the launch of Hi Scribe, a generative AI clinical documentation tool designed to automate and streamline the creation of clinical notes and supporting materials. Hi Scribe is built on top of the Huma AI foundation engine, known as Huma Intelligence (Hi), which also supports Hi Nurse (10X Nurse) and several other AI features. It is powered by insights from over 60 million consultations conducted by eConsult, one of Huma's portfolio companies acquired last year. Available within the Huma Cloud Platform (HCP), Hi Scribe automates clinical documentation in real-time, automatically generates structured clinical notes and enables direct integration into electronic health record (EHR) systems. It is designed for both in-person and virtual care settings, supporting clinicians across the full spectrum of digital health delivery. Already launched in the UK to 870 practices (covering 10 million patients) with writeback and coding capabilities for EMIS and SystmOne, the technology leverages Huma's strategic partnership with Google Cloud to deliver secure, scalable, and clinically compliant AI services to frontline healthcare workers. 'Administrative burdens—from documentation to process compliance and accurate billing—are among the greatest challenges facing healthcare systems globally,' said Dan Vahdat, CEO and Founder of Huma. 'Hi Scribe gives clinicians critical time back, allowing them to focus on what matters most: their patients. We're excited to roll this out across the 4,500+ health systems and clinics powered by Huma technologies around the world.' Regulatory-Compliant, Clinically Integrated Hi Scribe fully complies with regulations set forth by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a medical device and is part of Huma's globally compliant, enterprise-grade technology suite. It integrates directly into EHR systems, enabling clinicians to submit documentation seamlessly without disrupting workflow. As part of a broader care enablement strategy, Hi Scribe empowers clinicians with intelligent tools that reduce documentation burden while enhancing consistency and care quality. The launch follows recent NHS England guidance supporting the use of AI in clinical documentation and highlights Huma's role in driving innovation across public and private healthcare systems. With documentation consuming up to a third of clinical time globally, Huma is expanding access to Hi Scribe across its international footprint, which includes over 70 countries and 50 million engaged individuals. 'This tool brings clinicians' attention back to their patients,' said Dr. Murray Ellender, Head of UK Healthcare, Huma. 'By leveraging generative AI with strong regulatory governance, we are ensuring safe, effective, and efficient care. We are excited in the near future to start helping care providers with intelligent suggestions for next steps—ensuring that nothing is left unnoticed. We built this product in partnership with Opencast – a leading UK tech consultancy' 'Using Hi Scribe to transcribe my medical notes has transformed my day—saving me 2-3 minutes every consultation, reducing pressure, and letting me focus fully on my patients.' said Dr Ross Dyer-Smith, NHS GP. 'I have more headspace to think, listen, and make decisions. It's brought back more of the most satisfying part of practicing medicine—truly engaging and connecting with my patients.' U.S. Expansion with Wheel Huma's partner Wheel, the largest telemedicine provider-as-a-service platform in the U.S., will be among the first to bring Hi Scribe to virtual-first care environments in the U.S. through its Horizon platform. 'Clinicians shouldn't have to choose between delivering great care and managing documentation,' said Michelle Davey, CEO and Founder of Wheel. 'At Wheel, we're always looking for ways to make their jobs easier without adding friction. With Hi Scribe now integrated into Horizon, we're excited to be among the first to bring this kind of transformative AI technology to virtual care in the U.S.— giving our partners and their patients a better experience.' As Wheel brings Hi Scribe to market, it will be made available to enterprise organizations and digital health partners, expanding access to AI-powered documentation across U.S. virtual care delivery. Nationwide Rollouts Huma has also partnered with several countries to roll out this technology across all clinics as part of government-led digital health initiatives. Capturing clinical notes and automatically entering them into EMR systems remains a major challenge for many countries striving to accelerate the digitalization of their healthcare infrastructure. Ends Media images are here. About Huma Huma owns and operates leading digital and AI-first health products, including Aluna, myGP, GDm, eConsult, and more. All are supported by an AI-driven, software-defined, and federated-enabled operating model. Its portfolio powers over 4,500 hospitals and clinics, most major pharmaceutical companies, and CROs, with deployments across more than 70 countries. Huma's disease-agnostic cloud platform (HCP) is built for rapid, no-code configuration and seamless AI/ML integration. It has been recognized with FDA 510(k) Class II, EU MDR Class IIb, and other major regulatory certifications. These capabilities enable Huma to quickly launch new use cases and optimize acquired assets. Learn more at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
19-05-2025
- Business
- Yahoo
Huma sets stage for M&A strategy with Eckuity Capital partnership
British healthtech company Huma Therapeutics has partnered with Eckuity Capital to lay the foundations for an "aggressive" new M&A strategy. Huma develops AI-based tools for healthcare data integrations, patient wearables and other mobile devices to securely transmit data for use by healthcare professionals (HCPs). The company stated that its partnership with growth equity company Eckuity would support its development of technology infrastructure to support ongoing plans to acquire companies and launch digital solutions across the healthcare space. Huma also stated that its strategy will involve the ongoing acquisition of "complementary" companies to build a 'comprehensive digital ecosystem' that will support global health systems, CROs, and patients. According to Eckuity Capital managing partner Youssef Sebban, its role will be in helping Huma to acquire companies that 'may not fully realise' their potential on their own, yet become 'highly complementary' when integrated into Huma's cloud platform. Along with the Eckuity partnership, Huma has acquired Aluna (formerly Knox Medical Diagnostics). According to Huma, integrating the US company's respiratory monitoring offerings onto its platform will add 200 health systems and clinic chains to its existing 4,500 hospital network. Financial terms of the deal have not been publicly disclosed. Huma founder and CEO Dan Vahdat stated that its dual announcement marked a 'new chapter' for the company as it aims to build the world's 'most impactful' healthcare company. Vahdat said: 'By integrating Aluna's leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and most importantly, patients around the world." Aluna CEO Charvi Shetti said: 'Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide.' Huma received Class II clearance from the US Food and Drug Administration (FDA) for its platform as a software as a medical device (SaMD) in 2023, making it one of the first successful applicants to the FDA's eSTAR programme, in partnership with Health Canada. "Huma sets stage for M&A strategy with Eckuity Capital partnership" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Huma Announces Partnership with Eckuity Capital to Accelerate M&A and Acquires Aluna
New York, May 16, 2025 (GLOBE NEWSWIRE) -- Huma Therapeutics ('Huma'), the global healthcare AI leader accelerating digital transformation across care and research, today announced two major milestones: A global partnership agreement with Eckuity Capital to develop next-generation technology infrastructure—built on strong regulatory foundations—for the acquisition and launch of digital solutions in healthcare and research; and The acquisition of Aluna (also known as Knox Medical Diagnostics, Inc.), a leading U.S.-based company specializing in intelligent remote monitoring and management of respiratory x Aluna: (Front row, L to R) Charvi Shetty CEO of Aluna with Dan Vahdat CEO of Huma. Accelerating Growth Through M&ATo fuel its continued expansion, Huma is announcing partnership and investment with Eckuity Capital. This strategic collaboration with a leading healthcare growth equity firm will help provide the resources necessary to advance Huma's aggressive M&A strategy, with the goal of acquiring complementary companies to build a comprehensive digital ecosystem supporting health systems, pharmaceutical companies, CROs, and patients worldwide. Youssef Sebban, Managing Partner at Eckuity Capital, said: 'We help Huma acquire companies that, on their own, may not fully realize their potential—but when integrated into Huma's cloud platform, become highly complementary and transformative. This synergy not only amplifies their impact on the healthcare ecosystem but also drives outsized value creation for investors and shareholders.' Dan Vahdat, Founder and CEO of Huma, said: 'Today's announcements mark a new chapter for Huma as we strive to build the most impactful healthcare company in the world. By integrating Aluna's leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and—most importantly—patients around the world.' Huma's award-winning, disease-agnostic cloud platform has earned major regulatory certifications, including FDA 510(k) Class II and EU MDR Class IIb status. It supports over 4,500 hospitals and clinics and engages more than 50 million individuals across 70+ countries. Huma plays a pivotal role in national healthcare initiatives across the U.S., U.K., Germany, Greece, and Saudi Arabia, partnering with leading health systems, pharmaceutical companies, and CROs to redefine healthcare delivery. Strengthening Respiratory Health CapabilitiesWith the acquisition of Aluna, Huma significantly expands its reach in respiratory health, adding over 150 U.S.-based health systems and clinic networks to its growing global footprint. Based in San Francisco, Aluna is a market leader in respiratory patient monitoring and medical device manufacturing, including its proprietary spirometers. As part of the integration, Aluna's solutions will be relaunched on the Huma Cloud Platform, further enhancing their capabilities. The Huma Cloud Platform enables seamless, code-free configuration and AI/ML integration across a wide range of disease areas. The upgrade will also elevate Aluna's product classification to FDA Class II, unlocking greater clinical value for both patients and providers. All existing Aluna customers will gain access to Huma's comprehensive portfolio of disease management programs—spanning asthma, COPD, sleep apnea, and related conditions—serving approximately 500,000 contracted lives across these areas. This strategic move positions Huma to better serve the more than 25 million asthma patients and 15 million COPD patients in the United States alone, while reinforcing its leadership in chronic respiratory care on a global scale. Charvi Shetty, CEO of Aluna, remarked: 'Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide. We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.' Vishal Jain, Managing Partner at Eckuity Capital, said: 'We believe Dan and Huma's leadership team brings the much-needed bold vision to develop one of the most meaningful healthcare companies of the 21st century. The AI-led transformation of care that we will witness over the next two decades needs a reliable, real-time, and responsive infrastructure that very few companies can offer globally, and Huma is one of the most capable companies that can deliver on this promise.' Goodwin Proctor was exclusive legal advisor to Huma Therapeutics Limited on the Aluna transaction. Peak Technology Partners served as the exclusive financial advisor to Aluna on the transaction. Ends Media images are here. About HumaHuma is a healthcare AI company that owns and operates leading digital health applications. Its portfolio powers health systems, pharmaceutical companies, and CROs across more than 70 countries, transforming healthcare delivery at scale. Huma's disease-agnostic cloud platform is designed for rapid, no-code configuration and AI/ML integration, and has been recognized with FDA 510(k) Class II, EU/MDR Class IIb, and other major regulatory certifications. These capabilities enable the company to quickly launch new use cases and optimize acquired assets. Learn more at About Eckuity CapitalEckuity Capital is a global healthcare investment firm that supports high-growth companies at the inflection point in their growth cycle. The firm invests across Medtech, HealthTech, and Biotech Services to make a meaningful difference to patients, providers, and payors. With offices in New York and London, the firm focuses on solutions that bring positive changes to productivity, efficacy, distribution, and efficiency across the healthcare ecosystem. About AlunaAluna provides an AI-powered remote patient monitoring solution, integrating a portable, FDA-cleared spirometer, an intuitive mobile application, and a clinician portal. This integrated system enables live, real-world tracking of lung function and respiratory health. Developed by UC Berkeley Engineering graduates with firsthand experience of respiratory conditions, Aluna prioritizes user-friendliness and engagement, incorporating interactive features and rewards to encourage consistent use and adherence. Aluna's provider dashboard allows doctors to remotely access patient data, enhancing telemedicine capabilities and offering valuable health insights. The collection of real-time data in everyday settings allows for the assessment of respiratory medication and therapy effectiveness for individuals affected by asthma, COPD, cystic fibrosis, and other respiratory conditions. CONTACT: For further information please contact the Huma press office: Bilal Mahmood on or +44 (0) 771 400 7257.
